New drug cocktail targets Hard-to-Treat gut cancers
NCT ID NCT07446270
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests a combination of tunlametinib and anti-EGFR antibodies (cetuximab β or nimotuzumab) in 90 adults with advanced colorectal or pancreatic cancers that have RAS mutations and have not responded to standard treatments. The goal is to see if the combo shrinks tumors and improves survival, while monitoring safety. The study is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tunlametinib combined with cetuximab β or nimotuzumab
What this could lead to
If successful, this could offer a new treatment option for people with advanced colorectal or pancreatic cancers that have specific RAS mutations and have not responded to standard therapies.
What could go wrong
This is an early Phase 2 trial with only 90 participants, so results may not apply broadly. The combination may cause side effects or fail to improve outcomes significantly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.